A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.

ABSTRACT:

Purpose

Ceritinib is an orally bioavailable, small-molecule inhibitor of anaplastic lympoma kinase (ALK), insulin-like growth factor 1 receptor (IGFR1), and focal adhesion kinase (FAK), which are highly expressed in glioblastoma and many brain metastases. Preclinical and clinical studies indicate that ceritinib has antitumor activity in central nervous system (CNS) malignancies. This phase 0 trial measured the tumor pharmacokinetics (PK) and pharmacodynamics (PD) of ceritinib in patients with brain metastasis or recurrent glioblastoma.

Patients and methods

Preoperative patients with brain tumors demonstrating high expression of pSTAT5b/pFAK/pIGFR1 were administered ceritinib for 10 days prior to tumor resection. Plasma, tumor, and cerebrospinal fluid (CSF) samples were colle

SUBMITTER: Mehta S 

PROVIDER: S-EPMC9306447 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature